Key points are not available for this paper at this time.
High doses of methotrexate with citrovorum factor were administered to 10 patients with metastatic osteogenic sarcoma. A complete regression of pulmonary metastases was obtained in two patients and partial regression of tumor in two others. Side effects included nausea, vomiting, abdominal pain, stomatitis, bone marrow suppression, skin lesions, and renal impairment responding to additional citrovorum factor. The duration of response varied from 1 to 8+ months with complete regression of tumor persisting in one patient. Alternative schedules of methotrexate-citrovorum administration produced an additional response in one patient. Further studies with this maneuver are under investigation.
Norman Jaffe (Fri,) studied this question.